Table 2.
Univariate analysis of genomic factors associated with disease-free and overall survival
| Genomic Alteration | n | DFS HR (95% CI) | P | OS HR (95% CI) | P |
|---|---|---|---|---|---|
| TP53 | 15 | 1.7 (0.9–3.3) | 0.10 | 2.3 (1.0–4.9) | 0.04 |
|
| |||||
| NF1 | 11 | 0.8 (0.3–1.8) | 0.56 | 0.5 (0.2–1.6) | 0.25 |
|
| |||||
| CDKN2A | 10 | 1.1 (0.5–2.3) | 0.90 | 1.4 (0.6–3.4) | 0.44 |
|
| |||||
| NRAS | 10 | 1.2 (0.5–2.7) | 0.73 | 1.7 (0.6–3.3) | 0.29 |
|
| |||||
| MYOD1 | 9 | 1.1 (0.5–2.3) | 0.91 | 1.4 (0.6–3.3) | 0.46 |
|
| |||||
| MDM2 | 8 | 0.4 (0.1–1.3) | 0.12 | 0.8 (0.2–2.4) | 0.63 |
|
| |||||
| BCOR | 8 | 0.4 (0.1–1.8) | 0.26 | 0.3 (0.05–2.4) | 0.27 |
|
| |||||
| CDKN2B | 8 | 0.8 (0.3–1.9) | 0.56 | 1.2 (0.5–3.1) | 0.71 |
|
| |||||
| CDK4 | 7 | 1.8 (0.8–4.2) | 0.18 | 1.9 (0.6–5.3) | 0.25 |
|
| |||||
| GLI1 | 6 | 2.3 (0.9–5.9) | 0.09 | 2.6 (0.9–7.8) | 0.08 |
|
| |||||
| PAX3/7-FOXO1 | 22 | 1.7 (1.0–2.9) | 0.07 | 1.3 (0.7–2.6) | 0.44 |
|
| |||||
| TMB ≥2.8 (3rd quartile) | |||||
| All patients | 87 | 1.9 (1.1–3.4) | 0.03 | 2.3 (1.2–4.5) | 0.01 |
| Fusion negative | 65 | 2.1 (1.1–4.2) | 0.03 | 2.4 (1.1–5.5) | 0.03 |
| Fusion positive | 22 | 5.4 (1.0–28.4) | 0.05 | 29.5 (2.6–333.3) | 0.006 |
| Low/int risk | 60 | 2.1 (1.0–4.2) | 0.04 | 2.3 (1.0–5.2) | 0.04 |
| High risk | 27 | 4.0 (1.1–15.3) | 0.04 | 6.1 (1.6–24.0) | 0.009 |